Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 07.01.2026 FDNI.LN IE00BT9PVG14 400,002.00 USD 9,340,979.00 23.352  ...

ATLANTA--(BUSINESS WIRE)--TransactionTree, a retail technology company delivering a unified Customer360 Retail Operations Platform, today announced that Kevin Saum has been appointed Chief Executive Officer, effective immediately. Saum will lead the company’s next phase of growth as TransactionTree expands its platform and strengthens partnerships with mid-sized and enterprise retailers. Saum brings to TransactionTree a proven record of executive leadership in retail technology and enterprise s...

MINNEAPOLIS--(BUSINESS WIRE)--Concord appoints Chris Baker as Executive Chairman, underscoring the next phase of growth for this leading data and analytics solution provider....

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS). “ALS is a devastating and relentlessly progressive disease with profound unmet medical need, and patients urgently need new therapeutic options,” sai...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon™ peptide platform to drug historically undruggable targets, today announced the successful closing of a $305 million Series F financing. The round was co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors, with participation from new investors including...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company’s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca’s largest single manufacturing investment globally. The investment underpins AstraZeneca’s goal of generating $80...

GREENSBORO, N.C.--(BUSINESS WIRE)--Tanger® (“Tanger” or the “Company”) (NYSE: SKT), a leading owner and operator of outlet and open-air retail shopping destinations, announced today that its operating partnership, Tanger Properties Limited Partnership (the “Operating Partnership”), has priced and upsized the previously announced offering of $220 million aggregate principal amount of its 2.375% Exchangeable Senior Notes due 2031 (the “Notes”) in a private placement (the “Offering”) to persons re...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S (“Gubra”), a company specializing in peptide-based drug discovery and preclinical contract research services. “We are very...

CLEARWATER, Fla. & FREMONT, Calif.--(BUSINESS WIRE)--TD SYNNEX (NYSE: SNX) today announced financial results for the fiscal fourth quarter ended November 30, 2025. Consolidated Financial Highlights for the Fiscal 2025 Fourth Quarter GAAP ($ in millions, except earnings per share)                 Q4 FY25   Q4 FY24   Net Change from Q4 FY24 Revenue   $ 17,379     $ 15,845     9.7 % Gross profit   $ 1,195     $ 1,041     14.8 % Gross margin     6.87 %     6.57 %   30 bps Operating income   $ 399  ...

BARCELONA--(BUSINESS WIRE)--SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the Part B dose-expansion portion of the Phase 1/2 ASTRA clinical trial of SB-007, a dual adeno-associated viral (AAV) vector gene therapy for the treatment of Stargardt disease. Part B will evaluate two dose levels of SB-007 versus an untreated control in patients with the r...